Abstract 99P
Background
In the era of immunotherapy, whether removal of tumor -draining lymph nodes (TDLNs) should be removed as the traditional surgery way or should be surgical method or preserved preservation remains controversialis still unknown.
Methods
In this study, 42 mismatch repair deficient (dMMR) and 42 mismatch repairs proficient (pMMR) colon cancer patients were enrolled. Imaging data and single-cell RNA sequencing of tumor-draining lymph nodes were also investigated for comprehensive profiling of the microenvironment. The cells of tumor-draining lymph nodes in patients with dMMR colon cancer after neoadjuvant immunotherapy were analyzed to determine their T-cell phenotype.
Results
No significant differences in presurgical clinical characteristics were detected between the dMMR and pMMR groups. However, greater disease-free survival was observed in dMMR patients than in pMMR patients (p =0.02). Approximately 52.4% of patients with dMMR treated with a whole regimen of Pd-1 blockade (dMMR+Pd-1) achieved a pathological complete response (pCR). Eight of the 42 dMMR patients experienced bowel obstruction during treatment. The single-cell transcriptome revealed enrichment of naïve-like CD8+ T cells in the TDLNs of dMMR responders. In addition, we observed that macrophages in dMMR responder TDLNs were polarized toward the M1 phenotype. The altered microenvironment was accompanied by the complete eradication of malignant cells in TDLNs upon Pd-1 blockade treatment.
Conclusions
To maintain a durable response to ICIs, TDLN preservation could be considered a potential reservoir of memory T cells to sustain ICI responses and reduce the risk of relapse and progression in dMMR+Pd-1 blockade colon cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Sun Yat-sen University Cancer Center, Chinese Society of Clinical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract